{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:32:58Z","timestamp":1791419578967,"version":"4.3.3"},"reference-count":143,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NeurATRIS network"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.neurol.2014.09.004","type":"journal-article","created":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T12:19:36Z","timestamp":1415276376000},"page":"727-738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Gene therapy of the central nervous system: General considerations on viral vectors for gene transfer into the brain"],"prefix":"10.1016","volume":"170","author":[{"given":"C.","family":"Serguera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-P.","family":"Bemelmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2014.09.004_bib0005","series-title":"Man and His Future","article-title":"Biological Possibilities for the Human Species in the Next Ten Thousand Years","author":"Haldane","year":"1963"},{"key":"10.1016\/j.neurol.2014.09.004_bib0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/humc.2013.087","article-title":"Lessons learned from the clinical development and market authorization of Glybera","volume":"24","author":"Bryant","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.neurol.2014.09.004_bib0015","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose-escalation, open-label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2014.09.004_bib0020","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1517\/14712598.2013.845662","article-title":"Advances in adenovirus-mediated p53 cancer gene therapy","volume":"13","author":"Tazawa","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","article-title":"History of gene therapy","volume":"525","author":"Wirth","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.neurol.2014.09.004_bib0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrneurol.2013.56","article-title":"Progress in gene therapy for neurological disorders","volume":"9","author":"Simonato","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0035","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1126\/science.8382374","article-title":"An adenovirus vector for gene transfer into neurons and glia in the brain","volume":"259","author":"Le Gal La Salle","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.neurol.2014.09.004_bib0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ng0393-219","article-title":"A model system for in vivo gene transfer into the central nervous system using an adenoviral vector","volume":"3","author":"Davidson","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurol.2014.09.004_bib0045","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1093\/nar\/16.12.5690","article-title":"A new method to propagate defective HSV-1 vectors","volume":"16","author":"Geller","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.neurol.2014.09.004_bib0050","first-page":"739","article-title":"Transfer and expression of the lacZ gene in rat brain neurons mediated by Herpes-Simplex virus mutants","volume":"2","author":"Chiocca","year":"1990","journal-title":"New Biol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0055","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/ng0395-256","article-title":"Transplantation to the rat brain of human neural progenitors that were genetically modified using adenoviruses","volume":"9","author":"Sabate","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurol.2014.09.004_bib0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0006-8993(95)00596-I","article-title":"Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease","volume":"691","author":"Yoshimoto","year":"1995","journal-title":"Brain Res"},{"key":"10.1016\/j.neurol.2014.09.004_bib0065","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nm0496-424","article-title":"Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells","volume":"2","author":"Lacorazza","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2014.09.004_bib0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/jnci\/92.2.98","article-title":"Gene therapy death\u00a0\u2013\u00a0\u201ceveryone has to share in the guilt\u201d","volume":"92","author":"Jenks","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.neurol.2014.09.004_bib0075","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.neurol.2014.09.004_bib0080","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neurol.2014.09.004_bib0085","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.1073\/pnas.94.16.8818","article-title":"Intrastriatal injection of an adenoviral vector expressing glial cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease","volume":"94","author":"Bilang-Bleuel","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1006\/exnr.1999.7203","article-title":"Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease","volume":"160","author":"Mandel","year":"1999","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0095","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neurol.2014.09.004_bib0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.nbd.2011.12.030","article-title":"Gene therapy for Huntington's disease","volume":"48","author":"Ramaswamy","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurol.2014.09.004_bib0110","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0115","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1089\/hum.2005.16.618","article-title":"Adenovirus-mediated silencing of huntingtin expression by shRNA","volume":"16","author":"Huang","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0120","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0125","first-page":"46","article-title":"Non-viral gene delivery methods","volume":"14","author":"Wang","year":"2013","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0130","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2174\/1389201015666140608143719","article-title":"Nanobiotechnology-based drug delivery in brain targeting","volume":"14","author":"Dinda","year":"2014","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0135","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1128\/mcb.3.6.1123-1132.1983","article-title":"Design of a retrovirus-derived vector for expression and transduction of exogenous genes in mammalian cells","volume":"3","author":"Perkins","year":"1983","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0140","doi-asserted-by":"crossref","first-page":"6564","DOI":"10.1128\/JVI.74.14.6564-6569.2000","article-title":"A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression","volume":"74","author":"Li","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0145","doi-asserted-by":"crossref","first-page":"15414","DOI":"10.1073\/pnas.1110854108","article-title":"Anterograde or retrograde transsynaptic labeling of CNS neurons with vesicular stomatitis virus vectors","volume":"108","author":"Beier","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0150","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1099\/vir.0.19497-0","article-title":"Genetic content and evolution of adenoviruses","volume":"84","author":"Davison","year":"2003","journal-title":"J Genet Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2011.09.014","article-title":"Viral vectors for gene delivery to the central nervous system","volume":"48","author":"Lentz","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurol.2014.09.004_bib0160","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1073\/pnas.91.19.8802","article-title":"An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3","volume":"91","author":"Bett","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0165","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1073\/pnas.91.13.6196","article-title":"Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver","volume":"91","author":"Engelhardt","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0170","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/JVI.72.2.926-933.1998","article-title":"Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted","volume":"72","author":"Amalfitano","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0175","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/hum.1995.6.10-1343","article-title":"Characterization of an adenovirus gene transfer vector containing an E4 deletion","volume":"6","author":"Armentano","year":"1995","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0180","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1128\/jvi.71.4.3293-3298.1997","article-title":"A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging","volume":"71","author":"Parks","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0185","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.93.12.5731","article-title":"A new adenoviral vector: replacement of all viral coding sequences with 28kb of DNA independently expressing both full-length dystrophin and beta-galactosidase","volume":"93","author":"Kochanek","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0190","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0298-180","article-title":"Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity","volume":"18","author":"Schiedner","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurol.2014.09.004_bib0195","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/ng0393-224","article-title":"Transfer of a foreign gene into the brain using adenovirus vectors","volume":"3","author":"Akli","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurol.2014.09.004_bib0200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1215\/15228517-2007-012","article-title":"Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro","volume":"9","author":"Candolfi","year":"2007","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0205","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1089\/10430349950018166","article-title":"Adenovirus-mediated transgene expression in non-human primate brain","volume":"10","author":"Bohn","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0210","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.neurol.2014.09.004_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-005-9055-3","article-title":"Cell type- and region-dependent coxsackie adenovirus receptor expression in the central nervous system","volume":"78","author":"Persson","year":"2006","journal-title":"J Neurooncol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0220","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/jvi.69.4.2004-2015.1995","article-title":"Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses","volume":"69","author":"Yang","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0225","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-0270(96)00129-X","article-title":"Transient gene transfer to neurons and glia: analysis of adenoviral vector performance in the CNS and PNS","volume":"71","author":"Hermens","year":"1997","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.neurol.2014.09.004_bib0230","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1089\/hum.1997.8.9-1049","article-title":"Adenoviral vector-mediated gene expression in the nervous system of immunocompetent Wistar and T cell-deficient nude rats: preferential survival of transduced astroglial cells in nude rats","volume":"8","author":"Hermens","year":"1997","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0235","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/mthe.2000.0104","article-title":"Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system","volume":"2","author":"Zou","year":"2000","journal-title":"Mol Ther"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neurol.2014.09.004_bib0240","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.gt.3302612","article-title":"Gutless adenovirus: last generation adenovirus for gene therapy","volume":"12","author":"Alba","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0245","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pharmthera.2013.05.003","article-title":"Current status of local therapy in malignant gliomas--a clinical review of three selected approaches","volume":"139","author":"Juratli","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0250","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","article-title":"A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting","volume":"10","author":"Chiocca","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0255","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.neurol.2014.09.004_bib0260","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1073\/pnas.85.17.6460","article-title":"Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges","volume":"85","author":"Danos","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0265","series-title":"Fields virology","author":"Knipe","year":"2013"},{"key":"10.1016\/j.neurol.2014.09.004_bib0270","doi-asserted-by":"crossref","first-page":"a006890","DOI":"10.1101\/cshperspect.a006890","article-title":"HIV DNA integration","volume":"2","author":"Craigie","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.neurol.2014.09.004_bib0275","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0092-8674(00)80828-4","article-title":"HIV-1 genome nuclear import is mediated by a central DNA flap","volume":"101","author":"Zennou","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.neurol.2014.09.004_bib0280","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2009.319","article-title":"Recent advances in lentiviral vector development and applications","volume":"18","author":"Matrai","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0285","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery","volume":"72","author":"Zufferey","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0290","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/88115","article-title":"The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain","volume":"19","author":"Zennou","year":"2001","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0295","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1128\/JVI.73.4.2886-2892.1999","article-title":"Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors","volume":"73","author":"Zufferey","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0300","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1525-0016(03)00097-2","article-title":"Optimization of transgene expression at the posttranscriptional level in neural cells: implications for gene therapy","volume":"7","author":"Brun","year":"2003","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0305","doi-asserted-by":"crossref","first-page":"10920","DOI":"10.1128\/JVI.78.20.10920-10926.2004","article-title":"Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus","volume":"78","author":"Coil","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0310","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/jvi.43.3.871-875.1982","article-title":"Saturable binding sites for vesicular stomatitis virus on the surface of Vero cells","volume":"43","author":"Schlegel","year":"1982","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0315","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1073\/pnas.90.17.8033","article-title":"Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells","volume":"90","author":"Burns","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/exnr.1999.7178","article-title":"Lentiviral gene transfer to the non-human primate brain","volume":"160","author":"Kordower","year":"1999","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0325","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fncel.2013.00106","article-title":"Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors","volume":"7","author":"Merienne","year":"2013","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurol.2014.09.004_bib0330","doi-asserted-by":"crossref","first-page":"11382","DOI":"10.1073\/pnas.93.21.11382","article-title":"Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector","volume":"93","author":"Naldini","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0335","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/jnr.10719","article-title":"Targeted transgene expression in rat brain using lentiviral vectors","volume":"73","author":"Jakobsson","year":"2003","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.neurol.2014.09.004_bib0340","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neuroscience.2009.03.032","article-title":"Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors","volume":"161","author":"Nathanson","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neurol.2014.09.004_bib0345","doi-asserted-by":"crossref","first-page":"8873","DOI":"10.1128\/JVI.72.11.8873-8883.1998","article-title":"High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into non-dividing cells","volume":"72","author":"Mochizuki","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0350","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/glia.20795","article-title":"Engineered lentiviral vector targeting astrocytes in vivo","volume":"57","author":"Colin","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.neurol.2014.09.004_bib0355","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1089\/hum.2007.082","article-title":"Efficient gene transfer via retrograde transport in rodent and primate brains using a human immunodeficiency virus type 1-based vector pseudotyped with rabies virus glycoprotein","volume":"18","author":"Kato","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0360","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/hmg\/10.19.2109","article-title":"Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery","volume":"10","author":"Mazarakis","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurol.2014.09.004_bib0365","doi-asserted-by":"crossref","first-page":"e75896","DOI":"10.1371\/journal.pone.0075896","article-title":"Highly efficient retrograde gene transfer into motor neurons by a lentiviral vector pseudotyped with fusion glycoprotein","volume":"8","author":"Hirano","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2014.09.004_bib0370","doi-asserted-by":"crossref","first-page":"16148","DOI":"10.1074\/jbc.M114.549980","article-title":"Rabies virus envelope glycoprotein targets lentiviral vectors to the axonal retrograde pathway in motor neurons","volume":"289","author":"Hislop","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurol.2014.09.004_bib0375","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1002\/j.1460-2075.1991.tb04964.x","article-title":"Targeted integration of adeno-associated virus (AAV) into human chromosome 19","volume":"10","author":"Samulski","year":"1991","journal-title":"EMBO J"},{"key":"10.1016\/j.neurol.2014.09.004_bib0380","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","article-title":"Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue","volume":"72","author":"Duan","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0385","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of adeno-associated virus (AAV) and recombinant AAV vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu Rev Genet"},{"key":"10.1016\/j.neurol.2014.09.004_bib0390","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/mt.2008.103","article-title":"Recombinant adeno-associated virus transduction and integration","volume":"16","author":"Schultz","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0395","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ymthe.2005.11.015","article-title":"Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain","volume":"13","author":"Cearley","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0400","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1089\/10430349950018995","article-title":"Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression","volume":"10","author":"Lo","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0405","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.97.7.3428","article-title":"Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system","volume":"97","author":"Davidson","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0410","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JVI.76.2.791-801.2002","article-title":"Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity","volume":"76","author":"Rabinowitz","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0415","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","article-title":"Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system","volume":"10","author":"Burger","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0420","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.mt.6300331","article-title":"AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method","volume":"16","author":"Klein","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0425","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/mt.2009.216","article-title":"Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in non-human primates","volume":"18","author":"Dodiya","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0430","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/mt.2009.170","article-title":"Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from non-human primates","volume":"17","author":"Lawlor","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0435","doi-asserted-by":"crossref","first-page":"16129","DOI":"10.1523\/JNEUROSCI.2323-12.2012","article-title":"Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease","volume":"32","author":"Furman","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2014.09.004_bib0440","doi-asserted-by":"crossref","first-page":"e65646","DOI":"10.1371\/journal.pone.0065646","article-title":"Glial promoter selectivity following AAV-delivery to the immature brain","volume":"8","author":"von Jonquieres","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2014.09.004_bib0445","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.neuroscience.2008.05.059","article-title":"Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances neuroprotection from moderate but not severe hypoxia-ischemia","volume":"155","author":"Weller","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.neurol.2014.09.004_bib0450","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of Adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0455","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/mt.2008.166","article-title":"Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain","volume":"16","author":"Cearley","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0460","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0465","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0470","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/mt.2014.68","article-title":"Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and non-human primates by rAAVrh.10","volume":"22","author":"Yang","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0475","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.03.004","article-title":"Adeno-associated virus (AAV) gene therapy for neurological disease","volume":"69","author":"Weinberg","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurol.2014.09.004_bib0480","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/biot.200800284","article-title":"Adeno-associated virus-mediated gene delivery approaches for the treatment of CNS disorders","volume":"3","author":"Terzi","year":"2008","journal-title":"Biotechnol J"},{"key":"10.1016\/j.neurol.2014.09.004_bib0485","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/sj.gt.3302133","article-title":"Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo","volume":"10","author":"Wang","year":"2003","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0490","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/mt.2008.171","article-title":"Self-complementary AAV vectors; advances and applications","volume":"16","author":"McCarty","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0495","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0500","doi-asserted-by":"crossref","first-page":"7827","DOI":"10.1073\/pnas.0802866105","article-title":"Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses","volume":"105","author":"Zhong","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0505","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/mt.2010.172","article-title":"High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines","volume":"18","author":"Markusic","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0510","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/mt.2008.269","article-title":"High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors","volume":"17","author":"Petrs-Silva","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0515","doi-asserted-by":"crossref","first-page":"e59142","DOI":"10.1371\/journal.pone.0059142","article-title":"Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?","volume":"8","author":"Aslanidi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2014.09.004_bib0520","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1128\/JVI.77.1.423-432.2003","article-title":"Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production","volume":"77","author":"Bowles","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0525","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1128\/JVI.00254-08","article-title":"In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses","volume":"82","author":"Grimm","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0530","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nbt1182","article-title":"Directed evolution of adeno-associated virus yields enhanced gene delivery vectors","volume":"24","author":"Maheshri","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0535","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/gt.2012.20","article-title":"Directed evolution of novel adeno-associated viruses for therapeutic gene delivery","volume":"19","author":"Bartel","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0540","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.molcel.2005.12.011","article-title":"Mapping pathways and phenotypes by systematic gene overexpression","volume":"21","author":"Sopko","year":"2006","journal-title":"Mol Cell"},{"key":"10.1016\/j.neurol.2014.09.004_bib0545","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/emmm.201303744","article-title":"Mild expression differences of MECP2 influencing aggressive social behavior","volume":"6","author":"Tantra","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.neurol.2014.09.004_bib0550","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1750-1326-6-87","article-title":"Transgenic neuronal overexpression reveals that stringently regulated p23 expression is critical for coordinated movement in mice","volume":"6","author":"Gong","year":"2011","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurol.2014.09.004_bib0555","doi-asserted-by":"crossref","first-page":"9703","DOI":"10.1073\/pnas.87.24.9703","article-title":"Neuropathological changes in transgenic mice carrying copies of a transcriptionally activated Mos protooncogene","volume":"87","author":"Propst","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0560","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/asheducation.V2012.1.276.3807841","article-title":"Advances in stem cell transplantation and gene therapy in the beta-hemoglobinopathies","volume":"2012","author":"Payen","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.neurol.2014.09.004_bib0565","doi-asserted-by":"crossref","first-page":"e83398","DOI":"10.1371\/journal.pone.0083398","article-title":"Targeted expression of suicide gene by tissue-specific promoter and microRNA regulation for cancer gene therapy","volume":"8","author":"Danda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2014.09.004_bib0570","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/neuro.04.019.2009","article-title":"Short promoters in viral vectors drive selective expression in mammalian inhibitory neurons, but do not restrict activity to specific inhibitory cell types","volume":"3","author":"Nathanson","year":"2009","journal-title":"Front Neural Circuits"},{"key":"10.1016\/j.neurol.2014.09.004_bib0575","doi-asserted-by":"crossref","first-page":"16589","DOI":"10.1073\/pnas.1009158107","article-title":"A regulatory toolbox of mini promoters to drive selective expression in the brain","volume":"107","author":"Portales-Casamar","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0580","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/mtm.2013.5","article-title":"Targeted cns delivery using human minipromoters and demonstrated compatibility with adeno-associated viral vectors","volume":"1","author":"de Leeuw","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurol.2014.09.004_bib0585","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/v1030780","article-title":"The interaction between lentiviral integrase and LEDGF: structural and functional insights","volume":"1","author":"Hare","year":"2009","journal-title":"Viruses"},{"key":"10.1016\/j.neurol.2014.09.004_bib0590","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.taap.2007.08.008","article-title":"Comparison of toxicogenomic profiles of two murine strains treated with HIV-1-based vectors for gene therapy","volume":"225","author":"Zhao","year":"2007","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0595","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/sj.mt.6300159","article-title":"Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells","volume":"15","author":"Beard","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0600","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/mt.2014.3","article-title":"Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo","volume":"22","author":"Cesana","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0605","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/mt.2011.19","article-title":"Lentiviral vector integration profiles differ in rodent postmitotic tissues","volume":"19","author":"Bartholomae","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0610","doi-asserted-by":"crossref","first-page":"17684","DOI":"10.1073\/pnas.0606197103","article-title":"Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo","volume":"103","author":"Philippe","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2014.09.004_bib0615","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nm1365","article-title":"Effective gene therapy with non-integrating lentiviral vectors","volume":"12","author":"Yanez-Munoz","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2014.09.004_bib0620","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1097\/00001756-199707070-00005","article-title":"The immunosuppressant FK506 prolongs transgene expression in brain following adenovirus-mediated gene transfer","volume":"8","author":"Durham","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.neurol.2014.09.004_bib0625","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/hum.1997.8.3-253","article-title":"Immune responses to adenoviral vectors during gene transfer in the brain","volume":"8","author":"Kajiwara","year":"1997","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0630","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/JVI.03744-13","article-title":"Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques","volume":"88","author":"Leskowitz","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0635","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1006\/mthe.2000.0224","article-title":"Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain","volume":"3","author":"Thomas","year":"2001","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0640","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1089\/hum.1997.8.8-943","article-title":"Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response","volume":"8","author":"Smith","year":"1997","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0645","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/gt.2010.125","article-title":"Re-administration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression","volume":"18","author":"Cao","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0650","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/mt.2010.250","article-title":"The complex and evolving story of T cell activation to AAV vector-encoded transgene products","volume":"19","author":"Mays","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0655","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/hum.2005.16.741","article-title":"Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses","volume":"16","author":"Abordo-Adesida","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0660","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.neurol.2014.09.004_bib0665","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0670","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1566523054065057","article-title":"New recombinant serotypes of AAV vectors","volume":"5","author":"Gao","year":"2005","journal-title":"Curr Gene Ther"},{"issue":"189","key":"10.1016\/j.neurol.2014.09.004_bib0675","doi-asserted-by":"crossref","first-page":"ra176","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurol.2014.09.004_bib0680","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/mt.2008.100","article-title":"Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles","volume":"16","author":"Li","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0685","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1128\/JVI.78.12.6344-6359.2004","article-title":"Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain","volume":"78","author":"Peden","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.neurol.2014.09.004_bib0690","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ymthe.2003.12.005","article-title":"Striatal delivery of rAAV-hAADC to rats with pr-eexisting immunity to AAV","volume":"9","author":"Sanftner","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0695","doi-asserted-by":"crossref","first-page":"e63876","DOI":"10.1371\/journal.pone.0063876","article-title":"Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brain","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2014.09.004_bib0700","doi-asserted-by":"crossref","first-page":"21ra16","DOI":"10.1126\/scitranslmed.3000659","article-title":"Safety and efficacy of subretinal re-administration of a viral vector in large animals to treat congenital blindness","volume":"2","author":"Amado","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurol.2014.09.004_bib0705","doi-asserted-by":"crossref","first-page":"120ra115","DOI":"10.1126\/scitranslmed.3002865","article-title":"AAV2 gene therapy re-administration in three adults with congenital blindness","volume":"4","author":"Bennett","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurol.2014.09.004_bib0710","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/mt.2012.167","article-title":"Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses","volume":"21","author":"Ciesielska","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2014.09.004_bib0715","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nm1398","article-title":"Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer","volume":"12","author":"Brown","year":"2006","journal-title":"Nat Med"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378714010121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378714010121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:37:44Z","timestamp":1758519464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378714010121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":143,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0035378714010121"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2014.09.004","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy of the central nervous system: General considerations on viral vectors for gene transfer into the brain","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2014.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}